PLPL Company Description
Plandaí Biotechnology, Inc. (OTCQB: PLPL): Plandaí Biotechnology, Inc. and its subsidiaries develop highly bioavailable, phytonutrient rich extracts, which are being utilized to deliver a new family of drugs to safely and affordably treat a multitude of diseases and conditions.
Plandaí Biotechnology controls every aspect of the process, from growing the raw materials on its farms in South Africa, to producing the patented pending Phytofare™ extracts in-house allowing the Company to guarantee the continuity of supply as well as quality control throughout Targeted industries for the Company's products include food and beverage, cosmeceutical, wellness, nutraceutical, anti-aging, and pharmaceutical. For more information, please visit http://www.plandaibiotech.com
PLPL Products and Benefits
Phytofare™
"BIOAVAILABILITY" can be defined as a measurement of the amount of compound absorbed into the bloodstream.
In the market today, green tea high purity EGCG extracts, with an average selling price of $500/kg, have poor bioavailability of between 1-10%. Plandaí proprietary plant extracts has shown, in published studies, to have increased bioavailability. We believe through our studies that this is between 60-80%, far exceeding anything currently available today.
Our extracts include but are not limited to, gallate catechins from green tea, (catechin gallate (CG),epigallocatechin gallate (EGCG), gallocatechin gallate (GCG), and epicatechin gallate (ECG); carotenoids (lycopene)from tomatoes, as well as citrus bioflavonoids and limonoids. Furthermore, Plandaí's gallate catechin extract will be the active ingredient in formulated products supporting weight loss, antiaging, the lowering of blood cholesterol, the regulation of high blood pressure and controlling diabetes 1 and 2.
This means, that Plandaí's extracts deliver a more meaningful and beneficial dose at highly competitive prices to the consumer, in wellness terms
The Northern American and European natural extracts market are emerging and in a state of intense competition. The shift towards natural ingredients is driving the expansion of the natural extracts market. Among the flurry of ingredients competing in the natural extracts market, green tea extracts is a pioneer and one of the most prominent success stories. (Frost & Sullivan Research, 2011)
Current Projects
Senteeko Estate
Plandaí Biotechnology, Inc., through its wholly owned subsidiaries, farms over 7500 acres of luscious land in the Mpumalanga province of South Africa.
It farms a whole fruit basket of produce which it uses in its creation of highly bioavailable extracts, ranging from citrus to avocado pears to most notably over 2000 acres of tea.
The tea plant, Camellia Sinensis, is an evergreen shrub or tree and can grow to heights of 30ft though for cultivation is pruned to heights of 2-5ft.
Farming in South Africa is like no other country in the world and because of this we needed to make sure that we stacked the deck in our favour and employed only the best as ever y step of the product creation pathway is critical. With that in mind, our farming team has over 100 years of experience in managing farms in Southern Africa.
Green Tea Project
Green tea is one of the most widely consumed beverages in the world, second only to water, and its medicinal properties have been widely explored.
The tea plant, Camellia Sinensis, is a member if the Theaceae family and black, oolong and green tea are produced from its leaves.
It's an evergreen shrub or tree and can grow to heights of 30ft though for cultivation is pruned to heights of 2-5ft.
Gallate Catechin Extract Project
Polyphenols found in tea are more commonly known as flavanols or catechins and comprise 30-40% of the extractable solids of dried green tea leaves. There are 8 catechins in green tea and of those 8 the gallate catechins are;
Catechin gallate (CG)
Epicatechin-3-gallate (ECG)
Epigallocatechin (EGC)
Epigallocatechin-3-gallate (EGCG)
A number of the catechin polyphenols that are abundant in tea are reputed to have pharmacologically active properties. Within the plant, catechins are purported to be involved in the defence against pathogens, including insects, bacteria, fungi and viruses. Protection against bacterial and viral infection has also been observed against human pathogens as well as a plethora of other heath parameters. Clinical immunology 2010; 137,347-356
Unlike most green tea extracts on the market which focus on selling EGCG, which is the dominant gallate catechin, Plandaí Biotechnology extract, Phytofare™-Gallate Catechin extract (GCE), utilizes all four gallate catechins so as to benefit from their synergistic qualities as when a single phytochemical is isolated as an ingredient for a nutraceutical or pharmaceutical related product the synergistic activities created by the presence of the whole phytochemical is lost and therefore bioavailability or absorption is reduced.
By ingesting catechins individually, irrespective of the purity, van Amelsvoort et al. demonstrated that the galloyation of the catechins EGCG, ECG, CG and GCG, whilst having higher activities than those catechins without the galloyl moiety (EGC and CG) have reduced their absorption and are the least absorbed.
http://www.plandaibiotech.com/images/senteeko-2013-tea3.jpg
Research and Development
Citrus
Citrus is recognized as one of the most healthful components of the human diet. Much of the contribution of citrus in human health and nutrition is attributed to secondary metabolites present in the fruit including antioxidants, (ascorbic acid, flavanones, simple phenolics, carotenoids), folate and pectin.
From 2006 through 2009 the company undertook extensive documented citrus fruit studies with Sunkist growers at the fruit juice processing facilities in Ontario and Tipton, California to recover pectin, bioflavonoids, limonoids and limonene. Scientific validation was undertaken by USDA and Chromadex Inc. These investigations included considerable research of Sunkist production of FDA pharmaceutical extracts during the 1950 -1960’s of citrus bioflavonoids, limonoids, pectin, limonene and vitamin C. Furthermore, 104 Sunkist clinical publications on citrus bioflavonoids delivered conclusive evidence of citrus bioflavonoid efficacy in blood, vascular and capillary studies.
Based on these findings, the company second phase project is to process lemon fruits during the period the tea business is dormant and to recover a number of specific botanical extracts as active ingredients for
THE TREATMENT OF INFLAMMATORY CONDITIONS WITH CITRUS BIOFLAVONOIDS
The corticosteroid blood level is enhanced
Treatment of rheumatic fever is improved by inclusion of citrus bioflavonoids in the therapeutic regimen.
The frequency and severity of rheumatic epistaxis (nose-bled) is diminished by citrus bioflavonoids
Maintenance of Capillary Integrity
Athletic Injuries and Citrus Bioflavonoid Therapy
The Common Cold
A total of eleven studies were reviewed on the use of citrus bioflavonoids (Hesperidin) and ascorbic acid in the treatment of upper respiratory infections. Clinical trials Saylor (1956) with ninety nine patients with allergic and vasomotor rhinitis, (which so closely resembles the common cold with it nasal symptoms) observed complete or partial relief from 69% using Hesperidin, Chalcone and Sodium in daily divided doses.
WL Macon. Journal of Industry, Medicine and Surgery November 1956. A total of one hundred and twenty one persons who met rigid qualifications as having a common cold were studied with sixty two receiving a combination of lemon-orange flavonate glycoside, and ascorbic acid; and the other fifty nine receiving aspirin, phenacetin and caffeine, a well known palliative for the cold.
A total of forty six patients (74.2%) reported on the second day of taking the medication that they achieved complete or substantial relief when taking the bioflavonoid combination. In comparison only 30% (50.9%) taking ACP’s, the best known palliative obtained similar relief.
Tomatoes
Farming and Recovery from tomatoes of Bioavailable Lycopene, phytoene and phytofluene extracts
Lycopene, phytoene and phytofluene are carotenoid pigments, found in tomatoes and other red fruits. They are natural fat-soluble pigments (red, in the case of lycopene) which are synthesized by some plants and micro-organisms but not by animals. They serve as an accessory light-gathering pigment and also aid in the protection of these organisms against the toxic effects of oxygen and light.
Lycopene, phytoene and phytofluene are the most common antioxidant carotenoids in the human body which are poorly absorbed by the human body. They are naturally present in human plasma and tissues in higher concentrations than the other carotenoids. Its levels are affected by several biological and lifestyle factors. Because of its lypophilic nature, its concentrates in low-density and very-low-density lipoprotein fractions of the serum and are also found to concentrate in the adrenal, liver, testes, and prostate. However, unlike other carotenoids, lycopene, phytoene and phytofluene levels in serum or tissues do not correlate well with overall intake of fruits and vegetables.
Cardiovascular diseases, along with cancer, are the main mortality causes in Europe and other developed countries. Strong correlative evidence suggests that lycopene may provide important protection against cardiovascular diseases and cancer. However the missing links in the chain are bioavailability, metabolism, and molecular mechanisms of biological activities that are still unknown. www.lycocard.com
In published studies conducted with tomato growers of California between 2006 -2009, and supported by scientific analysis and investigations by USDA, Chromadex Inc., Craft Laboratories and other specialized laboratories, Phytofare™ carotenoid extracts showed considerable evidence of increased accessibility of lycopene, phytoene and phytofluene to extraction procedures on tomato, while changing the stereoisomeric profile of the carotenoids to one that was highly bioavailable and therefore more beneficial to consumers.
Active ingredient for novel anti-malaria-drug
Most efforts to design vaccine interventions against malaria has been focused on the blood stage of the parasite, which is responsible for the symptoms of the disease; and it is only now that a number of successful studies with gallate catechins have provides a good scientific rationale to develop a preventive drug against the pre-erythrocyte stages of the malaria parasite.
It is in the specific target area that a bioavailable green tea gallate catechin extract has been identified as the potential active ingredient of inhibiting the hexose uptake processes in infected erythrocytes; which is the primary mechanism of their anti-malarial activity and may involve interaction with alternative higher affinity target/s. Gallate catechins are able to inhibit motility and cause cytotoxcity through the form of several hydrogen structures and ionic bonds with proteins and thereby modulating their 3D structure. It has been shown that gallate catechins bind to adhesion molecules on the parasite surface and this impairs gliding, leading to an inactivation of the surface proteins and rendering the parasites immotile.
In published in-vitro and animal model studies, gallate catechins have shown inhibiting qualities and anti-malaria properties.
Plasmodium sporozoites are the forms of the malaria parasite injected into the host during a blood meal of the mosquito; and they are then deposited within the skin, where they can move at a speed of around 1 µm/s. Some sporozoites can enter blood vessels and are transported to the liver, where they invade hepatocytes to differentiate into red blood cell invading merozoites.
Gallate catechins bind to the intercellular adhesion molecule 1 (ICAM 1) on the endothelium thus blocking the adhesion of Plasmodium infected erythrocytes.
Inhibits Plasmodium falciparum growth in vitro and potentiates the anti-malarial effects of artemisinin.
Mechanism of inhibition of an enoyl-acyl carrier protein reductase of Plasmodium falciparum, resulting in the inhibition of the fatty acid biosynthesis in the parasite.
Malaria Journal Slavic et al. Malaria Journal 2011, 10:165
In 2012, Plandai Biotechnology is scheduled to undertake in-vitro and animal studies to validate its extract, Phytofare™-GCE, as an active ingredient for novel anti-malaria drugs.
PLPL Key Company Management
Roger Duffield - President & CEO
Roger Duffield has a significant background in the development and management of start-ups, private and public companies, especially in the United States, Europe and South Africa. His previous contributions in the United States public sector include Klinair Technologies Inc. and Rhombic Inc. relating to energy and hydrocarbon technologies. Through his extensive involvement with research and development programs with a number of academic institutions, including Penn State, University of Southern California, University of Washington, and the University of Limerick, Ireland, he was awarded two honorary Russian doctorates in Natural Sciences from the University of Moscow and Novosibirsk. In 2001 the Foundation for International Services, California recognized a degree in BSc. Chemical Engineering.
In 2001 he co-founded Global Energy Solutions Corporation Limited, Dublin, Ireland, recently acquired by Plandaí Biotechnology, Inc., and in 2003, the USA-based Research Company, CRS Technologies Inc. Mr. Duffield now heads this group of companies specializing, through private and public investment in the farming and recovery of highly valuable botanical extracts with unique characteristics.
Callum Baylis-Duffield - Vice President
Mr. Callum Baylis-Duffield is a graduate in International Business with French (BA Hons) from the University of the West of England. From 2007-2010, he was employed by Johnson and Johnson UK as a marketing & sales manager of a proprietary surgical device. Since 2010 he has been exclusively employed by Global Energy Solutions as the Director of Marketing and Sales and for the past 18 months has been based in South Africa where he has been integral to bringing the proprietary extract to market.
Mr Baylis-Duffield has been involved with the research and development of the Plandaí’s proprietary emulsions since 2004 and has worked extensively with the USA scientific team.
PLPL Contact Info
Plandaí Biotechnology, Inc.
2226 Eastlake Avenue East
#156
Seattle, WA 98102
Australia
Website: http://www.plandaibiotech.com
Phone: 435-881-8734
Email: info@plandaibiotech.com
PLPL SEC Filings
http://www.otcmarkets.com/stock/PLPL/filings
PLPL Headlines
http://finance.yahoo.com/q/h?s=PLPL+Headlines
Investigate more about PLPL @ http://www.otcmarkets.com/stock/PLPL/quote for more due diligence.
➔Be the first to get information about up-coming top penny stock alerts ➔ https://pennystockdivas.com/ $PLPL
$PLPL ~ Plandai Biotechnology, Inc. Corporate Presentation Brochure --->
ReplyDeletehttp://www.plandaibiotech.com/Plandai_web_brochure_2012v4/index.html
$PLPL extracts are being utilized to deliver a new family of drugs to safely & affordably treat a multitude of diseases & conditions http://www.plandaibiotech.com
ReplyDelete$PLPL Senteeko Estate - farms a whole fruit basket of produce which it uses in its creation of highly bioavailable extracts, ranging from citrus to avocado pears to most notably over 2000 acres of tea http://www.plandaibiotech.com/current-projects.html
ReplyDeletePlandaí, is a producer of highly bioavailable plant extracts for industries including health, wellness, nutraceutical, and pharmaceutical, expects to use its licensed Phytofare™ and Pheroid™ technologies to produce an FDA approved Phytofare™ cannabinoid complex that can address neural disorders without introducing the psychoactive element of THC to its treatments.
ReplyDeleteDuffield said, "Our research affirms that damage to the CB1 and CB2 brain receptors contributes to several neuron diseases. Cannabis is rich in neuron-beneficial phytocannabinoids including Δ9-THC; however, Δ9-THC taken in an oral preparation converts in the liver to 11-hydroxy metabolite. This new chemical demonstrates high levels of psycho-activity and is significantly less effective in scavenging free radicals. Essentially, you get the psychotropic aspects of the drug with none of the medicinal benefits."
$PLPL Benefits From Changes in Medical Marijuana Landscape in the U.S. 1/8/14 http://finance.yahoo.com/news/plandai-biotechnology-benefits-changes-medical-143000683.html?soc_src=mediacontentstory
ReplyDelete$PLPL believes that the phytonutrients in cannabis show excellent potential for treating and preventing a host of neuron and injury related brain diseases including Parkinson's, Alzheimer's, ALS, MS, and post-concussion syndrome
ReplyDeletehttp://finance.yahoo.com/news/plandai-biotechnologys-ceo-discusses-direction-134500146.html?soc_src=mediacontentstory
$PLPL news! Plandaí is Next to Ride the Marijuana Wave http://www.stockwatch.com/News/Item.aspx?bid=U-by410935-U%3aPLPL-20140114&symbol=PLPL®ion=U
ReplyDelete$PLPL Plandaí subsidiary, Cannabis Biosciences, Inc., will be developing and testing a botanical extract derived from cannabis, and the company its marijuana research will address neural disorders with. Specifically, the company believes that the phytonutrients in cannabis show excellent potential for treating and preventing a host of neuron and injury related brain diseases including Parkinson's, Alzheimer's, ALS, MS, epilepsy, PTSD and post-concussion syndrome http://www.stockwatch.com/News/Item.aspx?bid=U-by410935-U%3aPLPL-20140114&symbol=PLPL®ion=U
ReplyDelete$PLPL Plandai Biotechnology's Medical Marijuana Subsidiary Will Introduce Marijuana Industry to Unzipping Molecules http://www.stockwatch.com/News/Item.aspx?bid=U-i1082007-U%3aPLPL-20140115&symbol=PLPL®ion=U
ReplyDelete$PLPL news! Plandai Biotechnology, Inc. to Acquire License to Diego Pellicer Brand for Medical and Pharmaceutical Cannabis Extracts http://www.stockwatch.com/News/Item.aspx?bid=U-i1082357-U%3aPLPL-20140116&symbol=PLPL®ion=U
ReplyDelete$PLPL News! Plandai Biotechnology Partners With Well Known Brand in Cannabis Products http://www.stockwatch.com/News/Item.aspx?bid=U-i1082698-U%3aPLPL-20140117&symbol=PLPL®ion=U
ReplyDelete$PLPL is the first botanical extraction business in South Africa addressing the issues of unprofitable tea estates by making them viable through the harvesting of fresh green tea leaf for the sole purpose of extracting a bioavailable green tea gallate catechin extract http://www.plandaibiotech.com/investors.html
ReplyDelete$PLPL news! Marijuana Industry and Plandai Biotechnology Would Benefit From Obama's Shifting Opinion 1/21/14 http://www.stockwatch.com/News/Item.aspx?bid=U-i1083295-U%3aPLPL-20140121&symbol=PLPL®ion=U
ReplyDelete$PLPL is two steps ahead of the marijuana industry, and when all is settled, the company can hit the ground running -- ideally nationwide http://www.stockwatch.com/News/Item.aspx?bid=U-i1083295-U%3aPLPL-20140121&symbol=PLPL®ion=U
ReplyDelete$PLPL Plandaí Biotechnology, Inc. made a huge leap in solidifying itself as a leader in the marijuana industry http://www.stockwatch.com/News/Item.aspx?bid=U-i1083295-U%3aPLPL-20140121&symbol=PLPL®ion=U
ReplyDelete$PLPL Plandaí Sits at the Head of the Medical Marijuana Class 1/23/14 http://www.stockwatch.com/News/Item.aspx?bid=U-by411192-U%3aPLPL-20140123&symbol=PLPL®ion=U
ReplyDelete$PLPL Former Microsoft Executive Turned Marijuana Entrepreneur Should Put Plandai Biotechnology on the Map 1/24/14 http://www.stockwatch.com/News/Item.aspx?bid=U-i1084380-U%3aPLPL-20140124&symbol=PLPL®ion=U
ReplyDelete$PLPL Former Microsoft Exec marijuana Entrepreneur co-founded Diego Pellicer, Inc Shively plans to launch a study of the effectiveness of concentrated cannabis oil in the treatment of cancer and other illnesses
ReplyDeleteNEW YORK, NY -- (Marketwired) -- 01/24/14
Seattle is famous for its coffee and even more famous for Starbucks. That's the coffee chain no one ever imagined could blossom into a more than $50 billion business selling a cup of Joe. Well, don't look now but the city may soon be home to another retail chain that stakes its future on a single product, but this time it's marijuana and one man is trying to make that a reality. Former Microsoft exec Jamen Shively has become quite a recognizable name in the marijuana debate, and his recognition may very well be Plandaí Biotechnology's (OTCQB: PLPL) gain.
Shively is no stranger to marijuana as the great-great grandson of Diego Pellicer, the former Vice Governor of the Philippine Island of Cebu and the largest grower of hemp in the world in the late 1800s. Diego Pellicer once supplied hemp rope to the Spanish Armada during the Spanish American War.
The marijuana entrepreneur co-founded Diego Pellicer, Inc. to create the first retail brand of cannabis in the U.S. and eventually worldwide. Marijuana, both legal and black market, is a $100 billion a year industry in the U.S. alone, a number not lost on Shively, "It's a giant market in search of a brand. We would be happy if we get 40 percent of it worldwide."
It was likely his Microsoft stint that made Shively a media darling of sorts after he announced his vision to become the leader in both medical and recreational cannabis. Since that proclamation, he's found his name in many national headlines and has been a guest on just about every news program from CNN to FOX Business to ABC News. Dope Magazine even suggested Shively might be the "Bill Gates of Cannabis."
Shively also plans to launch a study of the effectiveness of concentrated cannabis oil in the treatment of cancer and other illnesses, and it's this desire to enter the medical side of marijuana that Plandaí hopes to capitalize on. Plandaí announced a week ago that it has partnered with Diego Pellicer, Inc. and Diego Pellicer Worldwide Inc. to use the Diego Pellicer name on its Phytofare™ medical and pharmaceutical cannabis extracts.
This is a genius idea for both Plandaí and Shively because it allows the biotech firm to build brand recognition for its cannabis products while the industry continues to deal with legislation, legalization and growth; meanwhile, for Shively, it allows his brand to be associated with medical marijuana products. Shively said of the agreement, "We couldn't be happier with our partnership with Plandaí. Their Phytofare™ technology appears to be years ahead of the competition as it relates to bioavailability and will help anchor the Diego brand as more states legalize cannabis for medical and/or recreational applications."
Let's face it no matter how controversial the debate, Jamen Shively has a platform and a rather large one at that, and it's that platform that should allow Diego Pellicer to become the brand at the tip of your tongue when you discuss cannabis. So, for Plandaí, that's not a bad ride to be on in what is the hottest debate in the country.
http://www.stockwatch.com/News/Item.aspx?bid=U-i1084380-U%3aPLPL-20140124&symbol=PLPL®ion=U
$PLPL Future in Marijuana Industry Boosted by Talk of Banking Access 01/27/14 http://www.marketwired.com/press-release/plandai-biotechnologys-future-marijuana-industry-boosted-talk-banking-access-otcqb-plpl-1872635.htm
ReplyDelete$PLPL Plandaí Biotechnology controls every aspect of the process, from growing the raw materials on its farms in South Africa, to producing the patented pending Phytofare™ extracts in-house allowing the Company to guarantee the continuity of supply as well as quality control throughout Targeted industries for the Company's products include food and beverage, cosmeceutical, wellness, nutraceutical, anti-aging, and pharmaceutical. For more information, please visit http://www.plandaibiotech.com
ReplyDeletePlandaí Biotechnology, Inc. (OTCQB: $PLPL ), a producer of highly bioavailable plant extracts for industries including health, wellness, nutriceutical, and pharmaceutical, today announced that it has been featured in the October 18th edition of Farmer's Weekly (www.farmersweekly.co.za). The article discusses the history of South African tea farming, the changes and renovations implemented by Plandaí to rejuvenate the tea industry, and the potential impact of the business on the local economy. http://www.farmersweekly.co.za/article.aspx?id=47167&h=Green-tea-revival
ReplyDelete$PLPL News!! pre-market Plandai Biotechnology's Cannabis Extracts Destined for Network and Cable News 1/30/14 http://finance.yahoo.com/news/plandai-biotechnologys-cannabis-extracts-destined-133000485.html?soc_src=mediacontentstory
ReplyDelete$PLPL Video Ron Throgmartin, CEO of Diego Pellicer - In an interview w/CBS “Legal pot dispensaries, high on profits” http://www.cbsnews.com/news/legal-pot-dispensaries-high-on-profits
ReplyDelete$PLPL is likely going to be mentioned again and again on television networks like CBS, CNN, CNBC, FOX, and ABC
ReplyDeleteNEW YORK, NY--(Marketwired - Jan 30, 2014) - When Plandaí Biotechnology (OTCQB: PLPL) entered into an agreement with Diego Pellicer and Diego Pellicer Worldwide to brand its Phytofare™ Cannabis extracts, one has to wonder if the company knew just how big a media platform its new partner has. If you're an investor in Plandaí, it might be time to get excited about who your company is partnered with. The media and its microphones showed up in large numbers at a Seattle press conference where marijuana entrepreneur and Diego Pellicer co-founder Jamen Shively announced he would be creating the first retail brand of marijuana in the United States.
Shively, a former Microsoft executive, was flanked by the former president of Mexico, Vicente Fox as he presented his plans to capture 40 percent of the worldwide marijuana market and answered a host of questions from the media. In the days, weeks and months following that event, Shively has been interviewed by just about every media publication, and he's made the rounds on all the network and cable news shows.
The media loves Jamen Shively, and if he has something to say, they'll provide the platform for him to say it. He's not alone though. Just yesterday CBS News called on Diego Pellicer's CEO, Ron Throgmartin, to discuss the industry since Colorado began selling recreational marijuana legally this month.
In the interview, Throgmartin predicted marijuana will be legalized nationwide in as little as two years. "I think by 2016 California will go legal. And, I think once a state the size of California goes, I think, the rest of the country follows."
One thing is clear, when Plandaí begins to market its Cannabis extracts under the Diego Pellicer brand, the company's name is likely going to be mentioned again and again on television networks like CBS, CNN, CNBC, FOX, and ABC. It's the genius in the partnership -- because while every other public company awaits legalization, Plandaí will be building its brand!
CBS News Interview: www.cbsnews.com/news/legal-pot-dispensaries-high-on-profits/
http://finance.yahoo.com/news/plandai-biotechnologys-cannabis-extracts-destined-133000485.html?soc_src=mediacontentstory
$PLPL +28% she soared over $3 bucks early!!! they may have ended 2013 slowly and started 2014 low, but the company is now catching fire!
ReplyDeletehttp://4.bp.blogspot.com/-KMiifQo_zj0/Uu-sh01jZkI/AAAAAAAADOE/04SJU_tCfgE/s1600/PLPL+2.3.JPG
$PLPL Marijuana Entrepreneur Jamen Shively Discusses Plandai Biotechnology, Branding Cannabis, and Legalization 2/4/14
ReplyDeletehttp://finance.yahoo.com/news/marijuana-entrepreneur-jamen-shively-discusses-140000607.html
[b]$PLPL nice daily chart ->[/b]
ReplyDeletehttp://1.bp.blogspot.com/-LVnPm6kAP3E/UvJMcNNEcJI/AAAAAAAADTo/9UqHsFMiNFw/s1600/chart+2.5.14.JPG
$PLPL Plandai Biotechnology Learning Branding and Marketing From Former Microsoft Executive Turned Marijuana Entrepreneur
ReplyDeleteNEW YORK, NY--(Marketwired - Feb 6, 2014) - Plandaí Biotechnology (OTCQB: PLPL) is in good hands when it comes to the future of branding and marketing its Phytofare(TM) cannabis extracts for use in both medical and pharmaceutical marijuana applications. While Plandaí continues to develop a full range of botanical extracts using its proprietary hydrodynamic sheering process, the company can follow the lead of its new branding partner, Diego Pellicer, Inc. and its co-founder Jamen Shively, to perfect a process as important as developing the extracts themselves -- marketing them.
The good news for Plandaí executives is they have a head start on the competition as businesses within the marijuana industry wait for regulations and nationwide legalization to play itself out in order to remove any legality concerns faced in using the drug for medicinal purposes. But, with the Cannabis debate still unfolding, former Microsoft executive turned marijuana entrepreneur, Jamen Shively, says there are advantages to building the brand now while others are idly waiting for the issue to be resolved.
"As an avid student and practitioner of the principles of marketing and branding, I can state with authority that 'first to mind' in getting our powerful brands out into the marketplace early on, are proving decisive in capturing long-term market share."
Shively has stated that he hopes to build the first retail brand of marijuana in the U.S., and eventually capture 40 percent of the market worldwide. It will be in those retail markets that Plandaí hopes to sell its cannabis extracts under the Diego Pellicer brand.
When asked how big the chain of stores can get in this country, Shively said, "It's difficult to predict, especially considering that the industry will evolve, eventually away from cannabis-only retail stores to packaged cannabis products sold in a variety of retailers, much as the alcohol industry evolved during the 1930s and 40s." He added, "Having said that, the next five years, at least, will see several hundred marijuana specialty retail stores opening throughout the U.S."
After years of helping steer Microsoft product releases, Plandaí picked a partner to learn from in Jamen Shively, who truly understands the importance of branding and knowing his audience, and in the end, it is Plandaí investors who should benefit.
http://www.stockwatch.com/News/Item.aspx?bid=U-i1087822-U%3aPLPL-20140206&symbol=PLPL®ion=U
$PLPL announced that it closed the license agreement with Diego Pellicer, Inc. which will permit the company use of the Diego Pellicer name for its Phytofare cannabis extract in medical and pharmaceutical marijuana applications
ReplyDelete2014-02-07 09:02 ET SEATTLE, WAvia eTeligis Planda Biotechnology, Inc. (OTCQB:PLPL), a producer of highly bioavailable plant extracts for industries including health, wellness, nutraceutical, and pharmaceutical, today announced that it closed the license agreement with Diego Pellicer, Inc. which will permit the company use of the Diego Pellicer name for its Phytofare cannabis extract in medical and pharmaceutical marijuana applications.
Roger Baylis-Duffield, Chairman and Chief Executive Officer of Planda Biotechnology, commented, "I want to congratulate the management teams of both Diego Pellicer and Planda for working diligently to move from a letter of intent to an executed license agreement in such a short time.Diego Pellicer has been the leading name in cannabis products for over a hundred years and represents everything that Planda stands for from a product standpoint; namely, an exhaustive dedication to quality.As we move forward towards having a market-ready product by the end of the year, we can commence building our branding and distribution channels."
Planda will produce the new Diego Pellicer Gold extracts in both capsules and cannabis oil (for vapor use) in Pheroid and non-Pheroid versions to appeal to the broadest range of medicinal consumers.
Under the terms of the executed license agreement, Planda can use the Diego Pellicer brand name for business-to-business sales and marketing in both domestic and international markets.Planda anticipates that the Diego Pellicer Gold extracts will be sold to various medical cannabis dispensaries in areas where such business is legal.
http://www.stockwatch.com/News/Item.aspx?bid=U-et1870130824-U%3aPLPL-20140207&symbol=PLPL®ion=U
$PLPL Completes $15.3 Million Funding Commitment
ReplyDeleteNEW YORK, NY- via eTeligis (Feb 10, 2014) - Planda Biotechnology, Inc. (OTCQB:PLPL), a producer of highly bioavailable plant extracts for industries including health, wellness, nutraceutical, and pharmaceutical, announced today that it has entered into a stock purchase agreement with Lincoln Park Capital Fund, LLC, a Chicago-based institutional investor, whereby Lincoln Park committed to invest, at the Company's sole option, up to $15.3 million of equity capital over the term of the purchase agreement including an initial investment of $300,000.
Roger Duffield, Chief Executive Officer of Planda, commented on the agreement, "This agreement with Lincoln Park gives Planda the flexibility to access capital over the next few years at prevailing market prices and as the need arises.As we enter into production and commence sales in the coming months, it is important to have a strong balance sheet and the ability to continue our research in green tea, citrus and to brand our cannabis extracts under the Diego Pellicer Gold label."
During the 30-month term of the stock purchase agreement the Company, at its sole discretion, has the right to sell to Lincoln Park up to an additional $15 million of its common stock, in amounts as described in the agreement and subject to certain conditions, which include the effectiveness of a registration statement with the U.S. Securities and Exchange Commission covering the sale of the shares that may be issued to Lincoln Park.The Company controls the timing and amount of any future investment and Lincoln Park is obligated to make purchases, if and when the Company decides, in accordance with the purchase agreement.
There are no upper limits to the price Lincoln Park may pay to purchase Planda common stock and the purchase price of the shares related to any future investments will be based on the prevailing market prices of the Company's shares immediately preceding the notice of sale to Lincoln Park.Lincoln Park has agreed not to cause or engage in any manner whatsoever, any direct or indirect short selling or hedging of the Company's shares of common stock.The agreement may be terminated by the Company at any time, at its sole discretion, without any monetary cost.The proceeds from this investment will be used for research, product development, marketing and general operating purposes.
A more detailed description of the agreement is set forth in the Company's Current Report on Form 8-K recently filed with the SEC which the Company encourages be reviewed carefully.
http://www.stockwatch.com/News/Item.aspx?bid=U-et1014843506-U%3aPLPL-20140210&symbol=PLPL®ion=U
$PLPL Video “Legal pot dispensaries, high on profits” Ron Throgmartin, CEO of Diego Pellicer Worldwide - In an interview with CBS Moneywatch correspondent Alexis Christoforous http://www.cbsnews.com/news/legal-pot-dispensaries-high-on-profits
ReplyDelete$PLPL Some nice dd -Plandai Biotechnology Offers Significant Growth Potential http://seekingalpha.com/article/2012401-plandai-biotechnology-offers-significant-growth-potential
ReplyDeleteAlthough the stock market has gotten off to a shaky start in 2014, there are still plenty of new investing opportunities. One company that has been a shining star thus far in 2014 is Plandai Biotechnology(OTCQB:PLPL). Investors looking for a small-cap company capable of participating in a fast-growing market that is riding a paradigm shift in government regulations should strongly consider Plandai Biotechnology.
Company Profile
The company develops highly bioavaiable, phytonutrient rich extracts that are being utilized to deliver a new family of drugs to safely and affordably treat a multitude of diseases and conditions. Plandai controls every aspect of the process, from growing the raw materials on its farms in South Africa to producing its patented Phytofare extracts-in-house, allowing the company to guarantee the continuity of supply as well as control throughout the entire process.
Entry into Cannabis
However, one of the primary reasons why Plandai Biotechnology stood out as a potential winning investment is because of the company's recent decision to form a new division called Cannabis Biosciences. The company announced on November 1, 2013, that it planned to create a new wholly-owned subsidiary to develop and test a new Phytofare botanical extract derived from cannabis. Given that the Plandai team already has specific and unique knowledge related to bioavailability and extraction capabilities, this is likely a wise decision as the company should have significant competitive advantages over its peers in the industry who simply want to ride the waves of the medical marijuana revolution. Following a series of studies and trials, Plandai's offerings have demonstrated the highest bioavailability in the industry. In some statistics, the absorption rate into the bloodstream was more than 8 times that of competing products. Moreover, competing products and approaches do not have the validation that Plandai has received via the recently formed relationship with Diego Pellicer. It is clear that the number one brand in the cannabis industry would seek out a partnership with the company that has produced the greatest bioavailability.
$PLPL Efforts to brand Plandaí's Cannabis extracts under the Diego Pellicer name are full steam ahead!!! http://www.stockwatch.com/News/Item.aspx?bid=U-i1089425-U%3aPLPL-20140212&symbol=PLPL®ion=U
ReplyDelete$PLPL Names Jamen Shively, co-founder of the Diego Pellicer to its Board of Directors
ReplyDeleteNEW YORK, NY--(Marketwired - Feb 13, 2014) - Plandaí Biotechnology, Inc. (OTCQB: PLPL), a producer of highly bioavailable plant extracts for industries including health, wellness, nutraceutical, and pharmaceutical, announced today that it has named Jamen Shively, a leading voice in the burgeoning marijuana industry and co-founder of the Diego Pellicer group of companies, to its Board of Directors. Mr. Shively will be filling the vacancy created with the resignation of David Rzepnicki, who recently resigned.
Roger Duffield, Chief Executive Officer of Plandaí, commented on the appointment of Mr. Shively to the Board, "Jamen brings a wealth of experience in both engineering and branding to Plandaí not to mention his bold leadership in the cannabis field. As a member of Plandaí's Board, Jamen will be instrumental in helping shape our corporate policy and direction as we move from being a research company into production and sales in the coming months."
Jamen Shively, age 45, has a background in engineering and marketing, with specialties in artificial intelligence, the modeling and optimization of complex networks, and the creation and positioning of new categories of products and services. Jamen co-founded Diego Pellicer Inc. in 2012, and built the brand from zero to the #1 most recognized brand of cannabis in the world in less than one year. Prior to founding Diego Pellicer, Jamen worked for Microsoft from 2003 to 2009 as Corporate Strategy Manager, where he focused on the creation and development of new categories of software products and online services. Preceding his Microsoft career he headed Shively International Inc., which built and operated both cybercafés and educational computer centers in Mexico. Just prior to founding Diego Pellicer Inc., Jamen founded and headed the online marketplace for the specialty food industry, Findood, winning first place in the Northwest Entrepreneur Network's First Look Forum Competition for the top new startup in 2010. Jamen completed his undergraduate work at U.C. Berkeley in Civil Engineering, and did graduate work at M.I.T. and U.C. Berkeley in Civil Engineering and Materials Science. He is a Fellow of the National Science Foundation.
Mr. Duffield added, "We are grateful for the years of service Mr. Rzepnicki provided to myself and to Plandaí over the past decade. He was one of the first to grasp the vision of the company and has been an unflagging ally over the years. As he focuses on his family and other business opportunities, we extend our sincerest thanks."
http://finance.yahoo.com/news/plandai-biotechnology-names-diego-pellicer-160500298.html
$PLPL Marijuana Entrepreneur Jamen Shively Goes Public with Plandai Biotechnology, Inc. 2/14/14 http://www.stockwatch.com/News/Item.aspx?bid=U-i1090100-U%3aPLPL-20140214&symbol=PLPL®ion=U
ReplyDelete$PLPL should have significant competitive advantages over its peers in the industry who simply want to ride the waves of the medical marijuana revolution. Following a series of studies and trials, Plandai's offerings have demonstrated the highest bioavailability in the industry. http://seekingalpha.com/article/2012401-plandai-biotechnology-offers-significant-growth-potential
ReplyDelete$PLPL Recent Marijuana News From Washington, D.C., Pivotal to Plandai Biotechnology's Success in the Industry
ReplyDeleteNEW YORK, NY -- (Marketwired) -- 02/19/14 Plandaí Biotechnology (OTCQB: PLPL) executives are certainly in favor of what 18 legislators are trying to accomplish with their letter to President Obama asking him to reclassify marijuana. They're likely equally as elated with news from the Administration last Friday that paves the way for legal banking between legitimate marijuana businesses and U.S. banks.
Things are moving very fast in the marijuana debate, and with each news event, there appears to be a real acceptance of the drug's future in this country. Last week's announcements certainly favor Plandaí's future in an industry that continues to be shaped by events.
The guidance issued by the Justice and Treasury departments is the latest step by the federal government toward enabling a legalized marijuana industry to operate in states that approve it. The intent is to make banks feel more comfortable working with marijuana businesses that are licensed and regulated.
This guidance will directly affect Plandaí at some point in the future as it works with Diego Pellicer to brand its Phytofare™ cannabis extracts. If successful, the letter sent to President Obama from 18 members of congress, will also directly affect Plandaí and its ability to use marijuana legally in its extracts and its research.
Legislators are asking Obama to use his authority to reclassify marijuana by removing it from the Schedule I category. Currently marijuana is viewed in the same category as heroin and LSD, and these 18 legislators say this status "makes no sense."
The letter read, "We request that you instruct Attorney General Holder to delist or classify marijuana in a more appropriate way, at the very least eliminating it from Schedule I or II." It went on to state: "Classifying marijuana as Schedule I at the federal level perpetuates an unjust and irrational system. Schedule I recognizes no medical use, disregarding both medical evidence and the laws of nearly half of the states that have legalized medical marijuana."
http://www.stockwatch.com/News/Item.aspx?bid=U-i1091080-U%3aPLPL-20140219&symbol=PLPL®ion=U
$PLPL Plandai Biotechnology Names Diego Pellicer Co-Founder and Cannabis Pioneer Jamen Shively as Vice President of Global Marketing
ReplyDeletehttp://www.stockwatch.com/News/Item.aspx?bid=U-et416454128-U%3aPLPL-20140220&symbol=PLPL®ion=U
$PLPL Recent Marijuana News From Washington, D.C., Pivotal to Plandai Biotechnology's Success in the Industry 2/19/14 http://www.stockwatch.com/News/Item.aspx?bid=U-i1091080-U%3aPLPL-20140219&symbol=PLPL®ion=U
ReplyDelete$PLPL - Future of Plandai Biotechnology's Products in Good Hands With Former Microsoft Executive Heading Up Global Marketing
ReplyDeleteNEW YORK, NY -- (Marketwired) -- 02/25/14 Today Plandaí Biotechnology (OTCQB: PLPL) named former Microsoft executive Jamen Shively as the company's Vice President of Global Marketing. Shively has an extensive and impressive resume in the world of business, and the company is confident he can deliver Plandaí's products on the world stage. According to Plandaí, Shively will be responsible for building brand awareness and marketing strategy for all of the company's operations. Needless to say, they found just the right man for the future of their products.
Since leaving Microsoft, Shively has become a marijuana entrepreneur who has the ability to command the media's attention. So, having Shively build brand awareness for the company's products, including, the Diego Pellicer® medical cannabis line as well as the Phytofare™ botanical extracts such as the Green Tea Catechin Complex and the Limonoid Glycoside Complex is a brilliant move by Plandaí executives.
Shively co-founded Diego Pellicer Inc. in 2012, and then built the brand into the most recognized brand of cannabis in the world in less than one year. Prior to founding Diego Pellicer, Jamen was a Corporate Strategy Manager for Microsoft from 2003 to 2009, where he focused on the creation and development of new categories of software products and online services.
Plandaí's CEO stated it is their goal to become the leading name in highly bioavailable botanical extracts for both nutraceutical and pharmaceutical applications. Jamen Shively is someone who can make that a reality, and he sounds more than ready to get started. "We have a unique opportunity with Plandaí's technology to fundamentally change how we address wellness, health and prevention through natural, botanical solutions."
Shively said he's also excited about the application of Plandaí's technologies to cannabis. He stated, "I believe they'll revolutionize the application of cannabis to preventive and therapeutic health, under the Diego Pellicer brand. This is the opportunity of a lifetime for me and for my colleagues at Plandai to change the world by improving the health and wellness of mankind through 100% natural plant extracts."
Shively's deep interest in the marijuana arena will serve Plandaí well, and his expertise will likely make the company a leading name in highly bioavailable botanical extracts just as the CEO expects.
http://www.stockwatch.com/News/Item.aspx?bid=U-i1091739-U%3aPLPL-20140225&symbol=PLPL®ion=U
$PLPL Guidance issued by the Justice and Treasury departments is the latest step by the federal government toward enabling a legalized marijuana industry to operate in states that approve it. http://www.stockwatch.com/News/Item.aspx?bid=U-i1091080-U%3aPLPL-20140219&symbol=PLPL®ion=U
ReplyDelete$PLPL - Plandai Biotechnology: A Natural Fit Into the Marijuana Industry
ReplyDeleteNEW YORK, NY -- (Marketwired) -- 03/03/14 Plandaí Biotechnology (OTCQB: PLPL) has a strong executive team in place, a well thought out business plan, and now it's time for the company to make its products the star. These products include Plandaí's Phytofare™ botanical extracts such as its Green Tea Catechin Complex and the Limonoid Glycoside Complex, as well as a line of Diego Pellicer® medical cannabis products. It is the latter could make the company a leader in the marijuana industry.
Plandaí entered the marijuana space in November 2013, and since that time, the biotech has moved quickly to develop its Phytofare™ cannabis extracts, it has also found a branding partner in Diego Pellicer, Inc., and it named former Microsoft executive Jamen Shively as the company's Vice President of Global Marketing to build and market the brand of cannabis extracts.
None of this should be a surprise however, as Plandaí very well could be the most natural fit of any publicly traded company into the marijuana arena. After all, Plandaí is a producer of highly bioavailable plant extracts for the health, wellness, nutraceutical, and pharmaceutical industries, so adding an additional plant (cannabis) for development into the lineup of botanicals the company already works with (green tea, limonoids) only enhances its product offerings.
But, it doesn't stop there. What sets Plandaí apart from many other companies working with botanicals is its hydrodynamic extraction process that allows the company to use science to achieve the most bioavailability from those plants.
While tetrahydrocannabinol (THC) has demonstrated the ability to reduce tumors and slow the progression of Alzheimer's, it is the second largest constituent of cannabis, cannabidiol (CBD), which doesn't have psychoactive properties that will likely be the primary focus of Plandaí's testing. A number of recent studies that show the healing and treatment benefits of cannabinoids in diseases like diabetes, ALS, Crohn's disease, multiple sclerosis, among others favor a biotech company like Plandaí that will engage in its own studies using cannabis.
http://www.stockwatch.com/News/Item.aspx?bid=U-i1094447-U%3aPLPL-20140303&symbol=PLPL®ion=U
$PLPL - Plandaí very well could be the most natural fit of any publicly traded company into the marijuana arena http://www.stockwatch.com/News/Item.aspx?bid=U-i1094447-U%3aPLPL-20140303&symbol=PLPL®ion=U
ReplyDelete$PLPL - Plandaí is a producer of highly bioavailable plant extracts for the health, wellness, nutraceutical, and pharmaceutical industries, so adding an additional plant (cannabis) for development into the lineup of botanicals the company already works with (green tea, limonoids) only enhances its product offerings http://www.stockwatch.com/News/Item.aspx?bid=U-i1094447-U%3aPLPL-20140303&symbol=PLPL®ion=U
ReplyDelete$PLPL Legalizing Medical Marijuana Gaining More Momentum in Mid-Term Election Year
ReplyDeleteNEW YORK, NY -- (Marketwired) -- 03/06/14
Plandaí Biotechnology (OTCQB: PLPL) is one of a handful of publicly traded companies that are eagerly anticipating the legalization of medical marijuana nationwide. Currently the drug is legal medicinally in 20 states and Washington, D.C., but in this election year, that number is likely to grow. In each national election year, the frenzy begins again and with it, a growing momentum that has the U.S. drawing closer to a nationwide acceptance.
Read More
http://www.stockwatch.com/News/Item.aspx?bid=U-i1095827-U%3aPLPL-20140306&symbol=PLPL®ion=U
This comment has been removed by the author.
ReplyDelete$PLPL former Microsoft executive Jamen Shively has been tapped to brand and market Plandaí's cannabis extracts. Shively, co-founder of Diego Pellicer, Inc., has witnessed the growing momentum and he anticipates legalization nationwide sooner rather than later http://www.stockwatch.com/News/Item.aspx?bid=U-i1095827-U%3aPLPL-20140306&symbol=PLPL®ion=U
ReplyDeleteMid day News! $PLPL Announces Acquisition of Minority Holders' Interest in South African Subsidiaries http://www.stockwatch.com/News/Item.aspx?bid=U-et476475000-U%3aPLPL-20140307&symbol=PLPL®ion=U
ReplyDelete$PLPL New acquisition means that once they are generating income from South Africa operations, they get to keep a much greater percentage of it
ReplyDeletehttp://finance.yahoo.com/news/plandai-biotechnology-announces-acquisition-minority-171500609.html
$PLPL pre-mkt News! Plandai Assumes Role in Legalizing Medical Marijuana in South Africa
ReplyDeleteSEATTLE, WA(eTeligis.com)Planda Biotechnology, Inc. (OTCQB: PLPL), a producer of highly bioavailable plant extracts for industries including health, wellness, nutraceutical, and pharmaceutical, announced today that it will assume a role in helping to craft legislation that is expected to result in the eventual legalization of marijuana for medical purposes in South Africa. Planda has retained the law firm Werksmans Attorneys, (LEX Africa) Sandton, South Africa, which includes health law as one of its specialties, to draft and file the company's comments on a recently introduced legislative bill that if passed, would effectively legalize medical marijuana in that country and pave the way for expanded research.
The Medical Innovation Bill was introduced in the legislature in February by terminally-ill IFP MP Mario Oriani-Ambrosini who stated in his introduction that, "...millions of people were going through the hell of being a cancer patient, and die and suffer, possibly unnecessarily, because government was not funding research and expediting approval for treatments where there was no profit to be made." Oriani-Ambrosini said tabling the bill to get the law changed was something he had to do. "This is my contribution to something that had to be done. I did not look for this fight... It found me."
Under current South African legislation, medical practitioners are legally denied the right to prescribe certain proven effective and harmless medication to their patients, which includes cannabis, on the basis that there are insufficient legally required double blind clinical studies. However, such studies are often considered economically unviable as cannabis, a plant that is in the public domain, cannot be patented by big pharmaceutical companies.
The bill's objectives are to establish one or more research hospitals where medical innovation can take place, especially with regard to the treatment and cure of cancer. The bill would also legalize the medical, industrial and commercial use of cannabis in South Africa in accordance with emerging world standards.
Oriani-Ambrosini also pointed out the potential economic benefits of legalized cannabis in South Africa, including tax revenue and jobs in agriculture and industrial production.
Commenting on the bill, Planda Vice President, Jamen Shively, stated, "As one of the few companies out there with a vested interest in medicinal cannabis research, and the stated goal of furthering such research, we see ourselves as duty-bound to help craft legislation and to support those institutions that are paving the way in this emerging field. The medical cannabis industry has been surviving solely on anecdotal evidence and limited medical research for too long. It is time to invest in legitimate, double blind human studies to confirm the effectiveness of cannabis therapy for not only cancers but also neural diseases such as Parkinson's, Alzheimer's, MS, PTSD and epilepsy. We applaud Mr. Oriani-Ambrosini for his pioneering legislation and look forward to doing our part in not only supporting his efforts but also funding research in South Africa if the bill eventually passes."
http://www.stockwatch.com/News/Item.aspx?bid=U-et410210341-U%3aPLPL-20140311&symbol=PLPL®ion=U
$PLPL -states - Medical Innovation Bill was introduced in the legislature in Feb by terminally-ill IFP MP Mario Oriani-Ambrosini who stated in his introduction that, "...millions of people were going through the hell of being a cancer patient, and die and suffer, possibly unnecessarily, because government was not funding research and expediting approval for treatments where there was no profit to be made." http://www.stockwatch.com/News/Item.aspx?bid=U-et410210341-U%3aPLPL-20140311&symbol=PLPL®ion=U
ReplyDelete$PLPL - will assume a role in helping to craft legislation that is expected to result in the eventual legalization of marijuana for medical purposes in South Africa http://www.stockwatch.com/News/Item.aspx?bid=U-et410210341-U%3aPLPL-20140311&symbol=PLPL®ion=U
ReplyDeleteCommenting on the mj bill, $PLPL Plandai Vice President, Jamen Shively, stated, "As one of the few companies out there with a vested interest in medicinal cannabis research, and the stated goal of furthering such research, we see ourselves as duty-bound to help craft legislation and to support those institutions that are paving the way in this emerging field. The medical cannabis industry has been surviving solely on anecdotal evidence and limited medical research for too long. It is time to invest in legitimate, double blind human studies to confirm the effectiveness of cannabis therapy for not only cancers but also neural diseases such as Parkinson's, Alzheimer's, MS, PTSD and epilepsy. We applaud Mr. Oriani-Ambrosini for his pioneering legislation and look forward to doing our part in not only supporting his efforts but also funding research in South Africa if the bill eventually passes."
ReplyDeletehttp://www.stockwatch.com/News/Item.aspx?bid=U-et410210341-U%3aPLPL-20140311&symbol=PLPL®ion=U
$PLPL - Plandai Vice President, Jamen Shively, stated, "As one of the few companies out there with a vested interest in medicinal cannabis research, and the stated goal of furthering such research, we see ourselves as duty-bound to help craft legislation and to support those institutions that are paving the way in this emerging field. The medical cannabis industry has been surviving solely on anecdotal evidence and limited medical research for too long. It is time to invest in legitimate, double blind human studies to confirm the effectiveness of cannabis therapy for not only cancers but also neural diseases such as Parkinson's, Alzheimer's, MS, PTSD and epilepsy. We applaud Mr. Oriani-Ambrosini for his pioneering legislation and look forward to doing our part in not only supporting his efforts but also funding research in South Africa if the bill eventually passes."
ReplyDeletehttp://www.stockwatch.com/News/Item.aspx?bid=U-et410210341-U%3aPLPL-20140311&symbol=PLPL®ion=U
$PLPL is one of the few cannabis OTC companies that is eagerly anticipating the legalization of medical marijuana nationwide. Currently the drug is legal medicinally in 20 states and Washington, D.C., but in this election year, that number is likely to grow. In each national election year, the frenzy begins again and with it, a growing momentum that has the U.S. drawing closer to a nationwide acceptance http://www.stockwatch.com/News/Item.aspx?bid=U-i1095827-U%3aPLPL-20140306&symbol=PLPL®ion=U
ReplyDelete$PLPL - Plandai Biotechnology, Inc. Completes Stage 1 of Senteeko Phytofare Factory, Readies for Production 3/18/14 http://www.stockwatch.com/News/Item.aspx?bid=U-et1458056597-U%3aPLPL-20140318&symbol=PLPL®ion=U
ReplyDelete$PLPL Video of the test Stage 1 of its state-of-the-art production facility on the Senteeko Tea Estate in South Africa http://youtu.be/l8kQqF_dJFQ
ReplyDelete$PLPL Announces Favorable Results for Human Clinical Trial
ReplyDelete2014-03-20 09:18 ET SEATTLE, WA(eTeligis.com)Planda Biotechnology, Inc. (OTCQB:PLPL), a producer of highly bioavailable plant extracts for industries including health, wellness, nutraceutical, and pharmaceutical, today announced favorable results from a recent human clinical trial involving a topical preparation of its Phytofare Catechin Complex. The study, which was undertaken by Prof. Banie Boneschans, North West University in Potchefstroom, South Africa, one of the leading research universities on the continent, was a double-blind study that tested the anti-aging properties of Phytofare. Specifically, the trial tested surface parameters (scaling and roughness), skin hydration, and skin elasticity.
The results, which were released to the company on March 17, stated that Phytofare yielded "statistically significant" results when compared to a baseline product.The trial involved 35 female Caucasian test subjects who applied two topical creams daily, the only difference being that one contained Phytofare, to skin patches which were tested at 14, 28, and 42 days.
The process of aging has a direct impact on the status of the skin surface. Skin imperfections, such as wrinkles and scaliness, reflect light differently than smooth, younger skin. A UVA-light camera with a black-and-white video sensor was used to photograph the skin surface and then measured the differences in texture. The study showed that the addition of Phytofare improved skin roughness by as much as 15% at 28 days, and a reduction in scaliness of the stratum corneum by 20%.Both of these measures were deemed "statistically significant" by the researcher.
In testing skin hydration, a Corneometer(R) was used to measure the change in the dielectric constant due to skin surface hydration.The study showed the Phytofare increased skin hydration by 15% at both 28 and 42 days, compared to .9% and 7.8% for the base product.The study pointed out that skin hydration improved significantly at 28 days and then maintained that level throughout the study.
The elastic properties reflect the skin's ability to return to its initial position after deformation and can be effected by chronological- and photo aging of the skin. Skin elasticity was evaluated by means of a Cutometer(R).The study showed an average improvement in skin elasticity of 1% at 42 days, though there was significant inter subject variation which rendered the results inconclusive with a recommendation for a larger sample size and longer duration for a future study.
Planda Vice President Jamen Shively commented, "This study validates the last decade of research and illustrate the benefits of enhanced bioavailability.We envision our Phytofare topical formulation serving as the backbone for a host of potential cosmetic products and look forward to sharing the results with our distribution partners as we near release of Phytofare to the market."
The company has placed an abstract of the study on its website:www.plandaibiotech.com
http://www.stockwatch.com/News/Item.aspx?bid=U-et54567527-U%3aPLPL-20140320&symbol=PLPL®ion=U
$PLPL - "Waiver" Could Dramatically Expedite Medical Marijuana Research 3/31/14 http://www.stockwatch.com/News/Item.aspx?bid=U-i1102337-U%3aPLPL-20140331&symbol=PLPL®ion=U
ReplyDelete$PLPL - Plandai Biotechnology, Inc. Commissions Stage 2 of Senteeko Phytofare Factory 4/1/14 http://www.stockwatch.com/News/Item.aspx?bid=U-et1796556585-U%3aPLPL-20140401&symbol=PLPL®ion=U
ReplyDeleteThe first product $PLPL - Planda will bring to the market is Phytofare Catechin Complex, which includes the entire catechin profile derived from green tea. Stages 2 and 3 are also set up to process lemons, which will lead to the introduction of Phytofare Limonoid Glycoside Complex later in the year.Citrus bioflavonoids are highly regarded not only for treating cold and flu symptoms but also as a potent anti-inflammatory useful for soft-tissue injuries and sports recovery http://www.stockwatch.com/News/Item.aspx?bid=U-et1796556585-U%3aPLPL-20140401&symbol=PLPL®ion=U
ReplyDelete$PLPL - final commission will take place this month as the company's engineers and scientists fine-tune the equipment, train staff, and test the output for conformity with the product profile http://www.stockwatch.com/News/Item.aspx?bid=U-et1796556585-U%3aPLPL-20140401&symbol=PLPL®ion=U
ReplyDelete$PLPL Closer to Unzipping the Magic of Phytofare in New Facility
ReplyDeleteNEW YORK, NY -- (Marketwired) -- 04/04/14 Plandaí Biotechnology, Inc. (OTCQB: PLPL) welcomes the month of April with a brand new state of the art production facility that is due to be fully operational sometime this month. Plandaí recently finished the all-important Stage 2 on the Senteeko Tea Estate in South Africa. It's this section of the factory that CEO Roger Duffield says "the magic of Phytofare" takes place. Plandaí will make its money and its mark in the biotechnology sector here as it's where the proprietary hydrodynamic sheering process will takes place.
Plandaí and its subsidiaries develop highly bioavailable, phytonutrient rich extracts which are being utilized to deliver a new family of drugs to safely and affordably treat a multitude of diseases and conditions. In order to develop these highly bioavailable extracts, it requires Plandaí's unique extraction process that uses live plant material grown on the tea estate and a combination of temperature and a unique wave of acoustic energy to release the living phytonutrients, rearranging the polyenes into a bio-compatible form.
Plandaí's CEO said of this process, "The magic of Phytofare involves unzipping the molecule to release the valuable phytonutrients, which we have now done for the first time on an industrial scale."
So, with stage 1 and 2 done, the company has turned to completing stage 3, the only section remaining between Plandaí and the introduction of its Phytofare™ extracts to the public. The third stage of Plandaí's process separates out the solids and any unnecessary elements, rendering pharmaceutical-grade, purified catechins in mainly nano-particle form.
As Plandaí reaches the finish line on the production facility, Duffield said, "It is exciting to see the culmination of over ten years of research and effort on the part of countless supporters." http://www.stockwatch.com/News/Item.aspx?bid=U-i1104126-U%3aPLPL-20140404&symbol=PLPL®ion=U
So, with stage 1 and 2 done, $PLPL - has turned to completing stage 3, the only section remaining between Plandaí and the introduction of its Phytofare™ extracts to the public. The third stage of Plandaí's process separates out the solids and any unnecessary elements, rendering pharmaceutical-grade, purified catechins in mainly nano-particle form http://www.stockwatch.com/News/Item.aspx?bid=U-i1104126-U%3aPLPL-20140404&symbol=PLPL®ion=U
ReplyDelete$PLPL Qualifies for Grant From South African Department of Trade & Industry
ReplyDelete2014-04-08 08:55 ET - News Release SEATTLE, WA(eTeligis.com)
Planda Biotechnology, Inc. (OTCQB: PLPL), a producer of highly bioavailable plant extracts for industries including health, wellness, nutraceutical, and pharmaceutical, today announced that it has qualified for and submitted the necessary paperwork to receive a grant from the South African Department of Trade and Industry (DTI). DTI grants are awarded based on qualifications relating to capital investment in new industry. The Company's extraction and processing factory in the Mpumalanga province in northern South Africa is considered a qualifying facility. DTI representatives will be touring the facility in the first week of May.
According to the DTI website (http://www.thedti.gov.za/about_dti.jsp), their strategic objective is to facilitate transformation of the economy to promote industrial development, investment, competitiveness and employment creation. The grant for which Planda qualifies is based on a fixed percentage of actual capital invested in the project. Depending on the final cost of the Senteeko manufacturing facility and the percentage of award as determined by the legislature, the grant is expected to be between 14-26 million Rands ($1.3-2.5 million US). The final amount is expected to be determined over the coming 90 days with the award being paid later in 2014.
Chairman and Chief Executive Officer Roger Duffield commented, "The South African government has been among our strongest supporters, first with the $13 million government-backed loan from the Land and Agriculture Bank, and now with an additional $1.3 to $2.5 million grant to help defray the cost of building our production facility. It is a testament to their belief not only in our technology but also our efforts to revitalize the region by creating jobs and operating under a zero carbon footprint model. The grant money will be useful in supporting our operations as the factory comes online and sales begin to ramp up in the coming months."
Planda first product to market will be Phytofare Catechin Complex, which includes the entire catechin profile derived from live green tea that is grown and processed on the Company's 8,000 acre Senteeko estate in South Africa. Later in 2014, and pending the results of a human clinical trial for treating cold and flu symptoms, the Company will begin producing Phytofare Limonoid Glycoside Complex, which contains citrus bioflavonoids that will also be extracted at the Senteeko facility using lemons bought from neighboring farms until its own lemon trees reach maturity.
About Planda Biotechnology, Inc.
Planda Biotechnology, Inc. and its subsidiaries develop highly bioavailable, phytonutrient rich extracts which are being utilized to deliver a new family of drugs to safely and affordably treat a multitude of diseases and conditions. Planda Biotechnology controls every aspect of the process, from growing the raw materials on its farms in South Africa, to producing its patented Phytofare extracts in-house, allowing the Company to guarantee the continuity of supply as well as quality control throughout the entire process. Targeted industries for the Company's products include beverage, cosmeceutical, wellness, nutraceutical, anti-aging, and pharmaceutical. For more information, please visit http://www.plandaibiotech.com
http://www.stockwatch.com/News/Item.aspx?bid=U-et971018422-U%3aPLPL-20140408&symbol=PLPL®ion=U
$PLPL - Planda first product to market will be Phytofare Catechin Complex, which includes the entire catechin profile derived from live green tea that is grown and processed on the Company's 8,000 acre Senteeko estate in South Africa. Later in 2014, and pending the results of a human clinical trial for treating cold and flu symptoms, the Company will begin producing Phytofare Limonoid Glycoside Complex, which contains citrus bioflavonoids that will also be extracted at the Senteeko facility using lemons bought from neighboring farms until its own lemon trees reach maturity.
ReplyDeletehttp://www.stockwatch.com/News/Item.aspx?bid=U-et971018422-U%3aPLPL-20140408&symbol=PLPL®ion=U
$PLPL - Plandaí and its subsidiaries develop highly bioavailable, phytonutrient rich extracts which are being utilized to deliver a new family of drugs to safely and affordably treat a multitude of diseases and conditions http://www.stockwatch.com/News/Item.aspx?bid=U-i1104126-U%3aPLPL-20140404&symbol=PLPL®ion=U
ReplyDelete$PLPL Plandai Biotechnology's Cannabis Extracts Could Further Shape Marijuana Debate
ReplyDeleteNEW YORK, NY -- (Marketwired) -- 04/11/14 Plandaí Biotechnology (OTCQB: PLPL) has a deal in place to brand and market its future cannabis extracts under the Diego Pellicer Gold label, and it could be those extracts and the company's work with cannabinoids that help shape public opinion in favor of using the drug medicinally. A Pew Research Center survey released last week found that 75 percent of Americans say they feel the legal sale and use of marijuana is inevitable whether they support it or not. While support for marijuana grows, Plandaí and its extracts could go a long way toward changing the minds of the drug's opponents.
In the survey, 54 percent of respondents favored legalizing the use of marijuana which is a dramatic change from just 4 years ago when in the same survey, only 41 percent thought pot should be legal. Make no mistake about it attitudes are shifting in favor of marijuana in this country, and recent interest is likely due to CNN Chief Medical Correspondent Sanjay Gupta's "Weed" documentaries that are educating more Americans on the realities of cannabis. "Weed" documentaries can be seen commercial free at www.stockmarketmediagroup.com/media.
Dr.Gupta himself was once a staunch opponent of legalizing marijuana, but he has since become a strong advocate for the use of cannabis. In those documentaries, Dr. Gupta has highlighted just how powerful the use of cannabinoids can be as a treatment for such things as seizures, pain management, cancer and many others.
Plandaí produces highly bioavailable plant extracts for industries including health, wellness, nutraceutical, and pharmaceutical, and will explore the use of both THC and cannabinoids to develop extracts and to pursue various pharmaceutical and nutraceutical applications. Dr. Gupta and a majority of Americans in general agree with Plandaí's CEO Roger Duffield who said, "The medicinal opportunities associated with phyto-cannabinoids are simply too great to ignore."
http://www.stockwatch.com/News/Item.aspx?bid=U-i1106142-U%3aPLPL-20140411&symbol=PLPL®ion=U